{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T23:37:24Z","timestamp":1780789044123,"version":"3.54.1"},"reference-count":84,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.cjca.2026.01.026","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T16:13:11Z","timestamp":1769184791000},"page":"1004-1017","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Nucleic Acid\u2013Based Therapies \u2014 The Next Frontier in Treating Dyslipidemias"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2861-5325","authenticated-orcid":false,"given":"Robert A.","family":"Hegele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2026.01.026_bib1","doi-asserted-by":"crossref","first-page":"e685","DOI":"10.1016\/j.jacl.2024.07.001","article-title":"Addressing residual risk beyond statin therapy: new targets in the management of dyslipidaemias-A report from the European Society of Cardiology Cardiovascular Round Table","volume":"18","author":"Mach","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.cjca.2026.01.026_bib2","first-page":"1553","article-title":"Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group consensus update","volume":"29","author":"Mancini","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2026.01.026_bib3","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S2213-8587(19)30264-5","article-title":"Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement","volume":"8","author":"Hegele","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10059","key":"10.1016\/j.cjca.2026.01.026_bib4","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2026.01.026_bib5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/MOL.0000000000000935","article-title":"Proprotein convertase subtilisin\/kexin type 9\u2013inhibition across different patient populations","volume":"35","author":"St\u00fcrzebecher","year":"2024","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.cjca.2026.01.026_bib6","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/MOL.0000000000000805","article-title":"Therapeutic application of genome editing in dyslipidemia","volume":"33","author":"Whittaker","year":"2022","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.cjca.2026.01.026_bib7","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1093\/eurheartj\/ehaf411","article-title":"Gene therapy and genome editing for lipoprotein disorders","volume":"46","author":"Gurevitz","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2026.01.026_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.93","article-title":"Familial hypercholesterolaemia","volume":"3","author":"Defesche","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.cjca.2026.01.026_bib9","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1093\/eurheartj\/ehv157","article-title":"Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment","volume":"36","author":"Wiegman","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2026.01.026_bib10","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","article-title":"2023 Update on European Atherosclerosis Society consensus statement on homozygous familial hypercholesterolaemia: new treatments and clinical guidance","volume":"44","author":"Cuchel","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2026.01.026_bib11","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jacl.2025.03.013","article-title":"Familial chylomicronemia syndrome: an expert clinical review from the National Lipid Association","volume":"19","author":"Javed","year":"2025","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.cjca.2026.01.026_bib12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.atherosclerosis.2022.04.003","article-title":"Lipoprotein(a) beyond the Kringle IV repeat polymorphism: the complexity of genetic variation in the LPA gene","volume":"349","author":"Coassin","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cjca.2026.01.026_bib13","first-page":"1129","article-title":"2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2026.01.026_bib14","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2026.01.026_bib15","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"41","author":"Bor\u00e9n","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2026.01.026_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2008.06.010","article-title":"Molecular basis of PCSK9 function","volume":"203","author":"Lambert","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cjca.2026.01.026_bib17","first-page":"S26","article-title":"Medications for lipid control: statins vs newer drugs","volume":"40","author":"McPherson","year":"2024","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2026.01.026_bib18","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/MOL.0000000000000954","article-title":"From clinical development to real-world outcomes with inclisiran","volume":"35","author":"Connolly","year":"2024","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.cjca.2026.01.026_bib19","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S2213-8587(21)00284-9","article-title":"Effective, disease-modifying, clinical approaches to patients with mild-to-moderate hypertriglyceridaemia","volume":"10","author":"Lewis","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cjca.2026.01.026_bib20","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/eurheartj\/ehab890","article-title":"Apolipoprotein C-III inhibition to lower triglycerides: one ring to rule them all?","volume":"43","author":"Hegele","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2026.01.026_bib21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/MOL.0000000000000875","article-title":"Triglyceride-rich lipoproteins, remnant-cholesterol, and atherosclerotic cardiovascular disease","volume":"34","author":"Ganda","year":"2023","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.cjca.2026.01.026_bib22","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/MOL.0000000000000905","article-title":"Triglyceride-rich lipoprotein cholesterol and cardiovascular risk","volume":"34","author":"Bilgic","year":"2023","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.cjca.2026.01.026_bib23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11883-024-01258-8","article-title":"The emerging potential of apolipoprotein C-III inhibition for ASCVD prevention: a state of the art review","volume":"27","author":"Maidman","year":"2024","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.cjca.2026.01.026_bib24","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1080\/17512433.2022.2094768","article-title":"Safety and efficacy of therapies for chylomicronemia","volume":"15","author":"Shamsudeen","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.cjca.2026.01.026_bib25","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/MOL.0000000000000979","article-title":"Emerging agents targeting triglycerides","volume":"36","author":"Prakash","year":"2025","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.cjca.2026.01.026_bib26","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/MOL.0000000000000898","article-title":"Angiopoietin-like 3 inhibition and the liver: less is more?","volume":"34","author":"Oostveen","year":"2023","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.cjca.2026.01.026_bib27","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/17446651.2023.2204932","article-title":"Low cholesterol states: clinical implications and management","volume":"18","author":"Gill","year":"2023","journal-title":"Expert Rev Endocrinol Metab"},{"key":"10.1016\/j.cjca.2026.01.026_bib28","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/MOL.0000000000000853","article-title":"New algorithms for treating homozygous familial hypercholesterolemia","volume":"33","author":"Tromp","year":"2022","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.cjca.2026.01.026_bib29","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/14712598.2024.2442455","article-title":"An up-to-date review of emerging biologic therapies for hypercholesterolemia","volume":"25","author":"Tomlinson","year":"2025","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.cjca.2026.01.026_bib30","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/MOL.0000000000000950","article-title":"Strategies for management of patients with elevated lipoprotein(a)","volume":"35","author":"Ellberg","year":"2024","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.cjca.2026.01.026_bib31","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cjca.2026.01.026_bib32","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/MOL.0000000000000855","article-title":"Consensus and guidelines on lipoprotein(a)\u2014seeing the forest through the trees","volume":"33","author":"Kronenberg","year":"2022","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.cjca.2026.01.026_bib33","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/MOL.0000000000000981","article-title":"Therapeutic advances in the Lp(a) battle: what do we know and what are the most awaited novelties in the field?","volume":"36","author":"Jean-Gilles","year":"2025","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.cjca.2026.01.026_bib34","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.3390\/ijms23052736","article-title":"Current advances in RNA therapeutics for human diseases","volume":"23","author":"Zogg","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cjca.2026.01.026_bib35","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.cjca.2026.01.026_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100416","article-title":"Antisense technology: a review","volume":"296","author":"Crooke","year":"2021","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cjca.2026.01.026_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.119114","article-title":"Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNA","volume":"403","author":"Brinton","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cjca.2026.01.026_bib38","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/35078107","article-title":"Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells","volume":"411","author":"Elbashir","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.cjca.2026.01.026_bib39","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s41587-023-02105-y","article-title":"RNA interference in the era of nucleic acid therapeutics","volume":"42","author":"Jadhav","year":"2024","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.cjca.2026.01.026_bib40","doi-asserted-by":"crossref","first-page":"16958","DOI":"10.1021\/ja505986a","article-title":"Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing","volume":"136","author":"Nair","year":"2014","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.cjca.2026.01.026_bib41","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41570-025-00763-x","article-title":"The impact of chemical reactivity on the quality and stability of RNA-LNP pharmaceuticals","volume":"9","author":"Kova\u010di\u010d","year":"2025","journal-title":"Nat Rev Chem"},{"key":"10.1016\/j.cjca.2026.01.026_bib42","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2026.01.026_bib43","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2026.01.026_bib44","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.jacc.2020.12.058","article-title":"Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis","volume":"77","author":"Wright","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2026.01.026_bib45","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.122.063460","article-title":"Efficacy, safety, and tolerability of inclisiran in patients with homozygous familial hypercholesterolemia: results from the ORION-5 randomized clinical trial","volume":"149","author":"Raal","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2026.01.026_bib46","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1161\/CIRCULATIONAHA.124.073233","article-title":"Efficacy and safety of inclisiran in adolescents with genetically confirmed homozygous familial hypercholesterolemia: results from the double-blind, placebo-controlled part of the ORION-13 randomized trial","volume":"151","author":"Wiegman","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2026.01.026_bib47","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41569-023-00892-0","article-title":"International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia","volume":"20","author":"Watts","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.cjca.2026.01.026_bib48","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","article-title":"Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 randomized clinical trial","volume":"9","author":"Gaudet","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cjca.2026.01.026_bib49","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2404143","article-title":"Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia","volume":"391","author":"Ballantyne","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2026.01.026_bib50","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa2409368","article-title":"Plozasiran for managing persistent chylomicronemia and pancreatitis risk","volume":"392","author":"Watts","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2026.01.026_bib51","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1038\/s41591-023-02494-2","article-title":"RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts","volume":"29","author":"Watts","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.cjca.2026.01.026_bib52","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa2404147","article-title":"Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia","volume":"391","author":"Rosenson","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2026.01.026_bib53","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S2213-8587(25)00290-6","article-title":"Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial","volume":"14","author":"Raal","year":"2026","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cjca.2026.01.026_bib54","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/S0140-6736(25)00507-0","article-title":"Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"405","author":"Ray","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2026.01.026_bib55","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.clinthera.2022.07.008","article-title":"Pharmacokinetics, pharmacodynamics, and tolerability of olpasiran in healthy Japanese and non-Japanese participants: results from a phase I, single-dose, open-label study","volume":"44","author":"Sohn","year":"2022","journal-title":"Clin Ther"},{"key":"10.1016\/j.cjca.2026.01.026_bib56","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O\u2019Donoghue","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2026.01.026_bib58","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1001\/jama.2023.21835","article-title":"Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a): a randomized dose-ascending clinical trial","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2026.01.026_bib60","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1001\/jama.2024.4504","article-title":"Single ascending and multiple-dose trial of zerlasiran, a short interfering RNA targeting lipoprotein(a): a randomized clinical trial","volume":"331","author":"Nissen","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2026.01.026_bib61","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cmet.2018.03.004","article-title":"RNA-targeted therapeutics","volume":"27","author":"Crooke","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.cjca.2026.01.026_bib62","doi-asserted-by":"crossref","first-page":"8796","DOI":"10.1093\/nar\/gku531","article-title":"Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice","volume":"42","author":"Prakash","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.cjca.2026.01.026_bib63","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2026.01.026_bib64","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","article-title":"Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"9","author":"Gouni-Berthold","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cjca.2026.01.026_bib65","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacl.2022.08.008","article-title":"Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: results of the BROADEN study: Volanesorsen in FPLD; the BROADEN study","volume":"16","author":"Oral","year":"2022","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.cjca.2026.01.026_bib66","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1056\/NEJMc2306575","article-title":"Volanesorsen to prevent acute pancreatitis in hypertriglyceridemia","volume":"390","author":"Alexander","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2026.01.026_bib67","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jacl.2022.06.005","article-title":"Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia","volume":"16","author":"Karwatowska-Prokopczuk","year":"2022","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.cjca.2026.01.026_bib68","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2026.01.026_bib69","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa2402309","article-title":"Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk","volume":"390","author":"Bergmark","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2026.01.026_bib70","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2026.01.026_bib72","doi-asserted-by":"crossref","DOI":"10.1172\/JCI148555","article-title":"Moving toward genome-editing therapies for cardiovascular diseases","volume":"132","author":"Musunuru","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cjca.2026.01.026_bib73","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/s41569-021-00669-3","article-title":"The use of new CRISPR tools in cardiovascular research and medicine","volume":"19","author":"Nishiga","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.cjca.2026.01.026_bib74","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1056\/NEJMp2314279","article-title":"Welcoming the era of gene editing in medicine","volume":"390","author":"Daley","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2026.01.026_bib75","doi-asserted-by":"crossref","DOI":"10.1126\/science.1258096","article-title":"Genome editing. The new frontier of genome engineering with CRISPR-Cas9","volume":"346","author":"Doudna","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.cjca.2026.01.026_bib76","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1161\/ATVBAHA.122.317963","article-title":"New approaches for targeting PCSK9: small-interfering ribonucleic acid and genome editing","volume":"43","author":"Oostveen","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cjca.2026.01.026_bib77","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.122.062132","article-title":"Efficacy and safety of an investigational single-course CRISPR base-editing therapy targeting PCSK9 in nonhuman primate and mouse models","volume":"147","author":"Lee","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2026.01.026_bib78","series-title":"Safety and pharmacodynamic effects of VERVE-101: an investigational DNA base editing medicine designed to durably inactivate the PCSK9 gene and lower LDL cholesterol\u2014interim results of the phase 1b Heart-1 trial","author":"Vafai","year":"2023"},{"key":"10.1016\/j.cjca.2026.01.026_bib79","series-title":"Nonclinical data demonstrate potent and precise inactivation of liver PCSK9 in vivo with clinical stage GalNAc base editing medicine, VERVE-102","author":"Rhode","year":"2025"},{"key":"10.1016\/j.cjca.2026.01.026_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2024.118496","article-title":"An investigational in vivo base editing medicine targeting ANGPTL3, VERVE-201, achieves precise and durable liver editing in nonclinical studies","volume":"395","author":"Lee","year":"2024","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cjca.2026.01.026_bib81","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1056\/NEJMoa2511778","article-title":"Phase 1 trial of CRISPR-Cas9 gene editing targeting ANGPTL3","volume":"393","author":"Laffin","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2026.01.026_bib82","article-title":"CTX320: an investigational in vivo CRISPR-based therapy efficiently and durably reduces lipoprotein(a) levels in non-human primates after a single dose [abstract]","volume":"148","author":"Morrow","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2026.01.026_bib83","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1161\/ATVBAHA.123.319748","article-title":"Epigenome editing durability varies widely across cardiovascular disease target genes","volume":"43","author":"Whittaker","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cjca.2026.01.026_bib84","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/s41586-024-07087-8","article-title":"Durable and efficient gene silencing in vivo by hit-and-run epigenome editing","volume":"627","author":"Cappelluti","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.cjca.2026.01.026_bib85","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2514428","article-title":"Evolocumab in patients without a previous myocardial infarction or stroke","volume":"394","author":"Bohula","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2026.01.026_bib86","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.122.059266","article-title":"Effect of vupanorsen on non\u2013high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol: TRANSLATE-TIMI 70","volume":"145","author":"Bergmark","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2026.01.026_bib87","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1021\/acsptsci.3c00185","article-title":"Looking back, moving forward: lipid nanoparticles as a promising frontier in gene delivery","volume":"6","author":"Pozzi","year":"2023","journal-title":"ACS Pharmacol Transl Sci"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X26000541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X26000541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T01:12:18Z","timestamp":1778202738000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X26000541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":84,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0828282X26000541"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2026.01.026","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nucleic Acid\u2013Based Therapies \u2014 The Next Frontier in Treating Dyslipidemias","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2026.01.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the Canadian Cardiovascular Society.","name":"copyright","label":"Copyright"}]}}